Brokerages Set Cerus Corporation (CERS) Price Target at $7.25

Cerus Corporation (NASDAQ:CERS) has earned an average recommendation of “Hold” from the seven research firms that are presently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $7.25.

A number of research analysts have recently commented on the stock. ValuEngine downgraded shares of Cerus Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. BidaskClub downgraded shares of Cerus Corporation from a “hold” rating to a “sell” rating in a research report on Friday, August 25th. Zacks Investment Research raised shares of Cerus Corporation from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. Cantor Fitzgerald reissued a “buy” rating and issued a $7.00 price objective on shares of Cerus Corporation in a research report on Wednesday, June 7th. Finally, BTIG Research reissued a “buy” rating and issued a $5.00 price objective on shares of Cerus Corporation in a research report on Sunday, May 28th.

WARNING: This report was first published by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2017/09/22/brokerages-set-cerus-corporation-cers-price-target-at-7-25.html.

In related news, insider Laurence M. Corash bought 92,796 shares of Cerus Corporation stock in a transaction that occurred on Friday, August 11th. The stock was acquired at an average price of $2.45 per share, with a total value of $227,350.20. Following the acquisition, the insider now owns 1,375,711 shares of the company’s stock, valued at approximately $3,370,491.95. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.40% of the company’s stock.

Several hedge funds have recently made changes to their positions in CERS. First Manhattan Co. boosted its holdings in shares of Cerus Corporation by 31.3% during the 2nd quarter. First Manhattan Co. now owns 42,000 shares of the biotechnology company’s stock worth $105,000 after buying an additional 10,000 shares during the period. UBS Asset Management Americas Inc. boosted its holdings in shares of Cerus Corporation by 59.3% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 48,377 shares of the biotechnology company’s stock worth $121,000 after buying an additional 18,000 shares during the period. Bellevue Group AG bought a new stake in shares of Cerus Corporation during the 1st quarter worth about $134,000. Russell Investments Group Ltd. bought a new stake in shares of Cerus Corporation during the 1st quarter worth about $137,000. Finally, Voya Investment Management LLC boosted its holdings in shares of Cerus Corporation by 22.0% during the 2nd quarter. Voya Investment Management LLC now owns 58,633 shares of the biotechnology company’s stock worth $147,000 after buying an additional 10,570 shares during the period. 58.26% of the stock is owned by institutional investors and hedge funds.

Cerus Corporation (NASDAQ:CERS) traded up 3.57% during midday trading on Friday, reaching $2.61. 870,464 shares of the company’s stock were exchanged. The company’s market cap is $284.85 million. The firm has a 50-day moving average price of $2.51 and a 200 day moving average price of $3.04. Cerus Corporation has a 52 week low of $1.93 and a 52 week high of $6.59.

Cerus Corporation (NASDAQ:CERS) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.16) EPS for the quarter, meeting analysts’ consensus estimates of ($0.16). Cerus Corporation had a negative net margin of 164.39% and a negative return on equity of 120.31%. The company had revenue of $9.53 million during the quarter, compared to the consensus estimate of $9.14 million. During the same quarter last year, the firm posted ($0.18) EPS. The company’s quarterly revenue was up 3.0% on a year-over-year basis. Analysts anticipate that Cerus Corporation will post ($0.68) EPS for the current year.

Cerus Corporation Company Profile

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company’s INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Receive News & Ratings for Cerus Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply